Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - furosemide - solution for injection - 10 mg/ml - sulfonamides, plain

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

accord healthcare limited - furosemide - solution for injection/infusion - 10 milligram(s)/millilitre - sulfonamides, plain; furosemide

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

pharmachemie bv - folinic acid - solution for injection - 25 mg/ml - detoxifying agents for antineoplastic treatment

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - folinic acid - solution for injection/infusion - 10 milligram(s)/millilitre - detoxifying agents for antineoplastic treatment; calcium folinate

Canada - Tiếng Anh - Health Canada

liebel-flarsheim canada inc - meglumine ioxitalamate; sodium ioxitalamate - solution - 513mg; 255mg - meglumine ioxitalamate 513mg; sodium ioxitalamate 255mg - roentgenography

Canada - Tiếng Anh - Health Canada

cheplapharm arzneimittel gmbh - ganciclovir (ganciclovir sodium) - powder for solution - 500mg - ganciclovir (ganciclovir sodium) 500mg - nucleosides and nucleotides

Canada - Tiếng Anh - Health Canada

fresenius kabi canada ltd - ganciclovir (ganciclovir sodium) - powder for solution - 500mg - ganciclovir (ganciclovir sodium) 500mg - nucleosides and nucleotides

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - calcium folinate - solution for injection - 3mg/1ml

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - furosemide - solution for injection - 10mg/1ml

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir